Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SathalapRx
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SathalapRx is a preclinical-stage biotechnology company dedicated to developing novel therapeutic interventions for neurodegenerative diseases and aging-related conditions. The company's primary focus is on the modulation of autophagy, a critical cellular process for degrading and recycling damaged proteins and organelles. By leveraging its proprietary platform to identify and optimize small molecule activators of autophagy, SathalapRx aims to address the underlying protein aggregation and cellular dysfunction characteristic of diseases like Parkinson's and Alzheimer's. The company is currently advancing several discovery-stage programs targeting specific components of the autophagy pathway to restore proteostasis and promote neuronal health.
- Therapeutic areas
- NeurologyOther
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on SathalapRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SathalapRx.